Fig. 1 · Structure

Documents & Downloads

Mdivi-1

Cat. No. A14316 CAS 338967-87-6

DRP1 inhibitor

Mdivi-1 is a selective cell-permeable inhibitor of mitochondrial division DRP1 (dynamin-related GTPase) and mitochondrial division Dynamin I (Dnm1) with IC50 of 1-10 uM.

In Stock

Publications for Mdivi-1

2 publications citing this product

  1. Umut Kerem Kolac, .et al. , Mol Biol Rep, 2023, Jan;50(1):493-506 PMID: 36352179
  2. KOLAC UK, .et al. , Research Square, 2022, 03 Jun

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Mdivi-1 requires caution as a mechanistic probe. In recombinant human Drp1 assays, inhibition was weak (Ki > 1.2 mM), while cellular assays showed inhibition of complex I-linked respiration at micromolar concentrations. These results limit claims of selective direct Drp1 inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Dynamin1 1 μM-10 μM

In Vitro

In the ganglion cell layer (GCL), Mdivi-1 exhibits strong immunoreactivity. Twelve hours following ischemic induction, Mdivi-1 significantly increases protein expression within the GCL. It notably reduces the expression of GFAP protein without altering Drp1 protein expression. In the normal murine retina, Mdivi-1 primarily localizes to the inner plexiform layer, ganglion cell layer, outer plexiform layer, and inner nuclear layer. Early in the development of the ischemic murine retina, there is a marked increase in the protein expression of Mdivi-1 and glial fibrillary acidic protein (GFAP). Mdivi-1 inhibits apoptosis in the ischemic retina and significantly increases the survival rate of retinal ganglion cells (RGC) two weeks post-ischemia.

Mdivi-1 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Mdivi-1 from 3 published references. In vitro models include primary rat cortical neurons and COS-7 cells. In vivo models include male C57Bl6J mice, 23 weeks and 83 weeks.

Mdivi-1 In Vitro Studies

Mdivi-1 reduced mitochondrial oxygen consumption in primary rat cortical neurons and COS-7 cells. Washout restored respiration after a 1-hour exposure, but after 5 hours inhibition persisted in neurons while COS-7 respiration recovered, showing that reversibility depends on exposure and cell model. [1]

A Research Square preprint using Adooq A14316 reported that 100 μM mdivi-1 for 3 hours reduced ROS positivity in high-glucose BeWo cells. MTT readouts did not change significantly with inhibitor treatment. These cell-based findings do not establish direct Drp1 inhibition or therapeutic efficacy. [2]

Complex I-linked respiration and exposure-dependent reversibility

Cell-based study · Primary rat cortical neurons (mixed-sex E18 cortex, DIV10–14) and COS-7 cells [1]

Acute respiration inhibition was consistent with an effect on complex I-linked electron flow. One-hour exposure was reversible after washout; after five hours, neuronal inhibition persisted while COS-7 respiration recovered.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal and FCCP-stimulated maximal mitochondrial oxygen consumptionQualitative response Inhibited in neurons at 50 and 100 μM; inhibited in COS-7 cells over the tested 25–100 μM range.[1]
Substrate dependence and washout rescueQualitative mechanistic controls Pyruvate/malate-linked respiration inhibited by 50 μM; succinate-linked respiration spared. Inhibition recovered after washout following 1 h at 50 μM.[1]
Maximal OCR after washoutExposure-dependent response After 5 h at 50 μM, inhibition remained reversible in COS-7 cells but became irreversible in neurons over the assay observation period.[1]

Literature-Reported Treatment Conditions

Treatment concentration
25–100 μM for acute OCR; 50 μM for substrate and washout comparisons
Exposure duration
Acute OCR traces; 1 or 5 h before washout as specified in Figure 1
Method
Extracellular-flux oxygen consumption in intact or permeabilized cells
Vehicle
DMSO control; assay medium contained 4 mg/ml fatty-acid-free BSA
Co-treatment
Respiratory substrates, FCCP and ETC inhibitors used as mechanistic assay controls, not therapeutic combinations.
Reported limits
Exact DMSO percentage for the OCR experiments was not located in the selected methods.
Methods and source locations

Compound reported in the paper: Mdivi-1

Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.

Figure 1A–F; Results, Mdivi-1 Inhibits Complex I-dependent Mitochondrial O2 Consumption; Oxygen Consumption by Cells methods

Basal and FCCP-stimulated maximal mitochondrial oxygen consumption: Figure 1A–B: traces mean ± SD, 3 wells, representative of 4 independent experiments with 2–3 wells each; antimycin A distinguished mitochondrial from residual OCR. — Figure 1A–B and caption; accompanying Results

Substrate dependence and washout rescue: Figure 1D–E: permeabilized neurons, ADP-stimulated respiration; rotenone comparison and succinate rescue. Does not establish a direct molecular binding site. — Figure 1D–E; caption and Results

Maximal OCR after washout: Figure 1F: 1- and 5-hour pretreatment, washout, maximal OCR measurement. — Figure 1F and accompanying Results

Weak inhibition of recombinant human Drp1 GTPase

Biochemical assay · Recombinant human Drp1, 5 μM protein [1]

Global fitting of substrate kinetics yielded Ki > 1.2 mM. A non-hydrolyzable GTP analogue strongly inhibited the assay, providing a positive control. This result limits interpretation of mdivi-1 as a selective direct human Drp1 inhibitor.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Recombinant human Drp1 GTP hydrolysisKi > 1.2 mM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–100 μM mdivi-1
Exposure duration
NADH oxidation monitored for 40 min at 25 °C
Method
Continuous coupled GTPase assay; 5 μM Drp1, varying GTP
Vehicle
5% DMSO
Co-treatment
GTP-γ-S positive inhibitory control; not a co-treatment arm.
Methods and source locations

Compound reported in the paper: Mdivi-1

Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.

Figure 3 and caption; Results, Mdivi-1 Fails to Elongate Mitochondria or Inhibit Drp1 GTPase Activity; GTPase Activity Assay methods

Recombinant human Drp1 GTP hydrolysis: Uncompetitive global fit; Figure 3 gives data and SEM from 3 independent Drp1 preparations. Ki is a fitted inhibition constant, not a cellular treatment dose or IC50. — Figure 3, printed fit annotation and caption; GTPase Activity Assay

ROS-positive fraction in glucose-exposed BeWo cells

Cell-based study · Human BeWo trophoblast cell line (ECACC 86082803), 5.5 or 25 mM glucose [2]

The preprint reports reduced ROS positivity with 100 μM mdivi-1 in high-glucose cells, without a significant MTT change attributable to inhibitor treatment. This is a cellular response and does not establish direct Drp1 target engagement or clinical benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fraction of ROS-positive cellsDirection and reported significance Reduced versus the 25 mM glucose DMSO control at 100 μM (P < 0.001); no significance marker for mdivi-1 versus the 5.5 mM glucose control.[2]
MTT absorbance after inhibitor exposureReported null comparison Inhibitor treatment did not significantly alter MTT viability readout; this does not establish equivalence or absence of toxicity.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM for Figure 3A–B ROS; 50 and 100 μM for Figure 4E MTT context
Exposure duration
3 h inhibitor treatment after glucose exposure; 48 h glucose condition selected for subsequent experiments
Method
Mdivi-1 administered separately from dynasore and P-110 comparator treatments
Vehicle
DMSO below 1%, also applied to control cells
Reported limits
Exact DMSO percentage and an osmolarity-matched control were not located in the acquired v1 methods.
Methods and source locations

Compound reported in the paper: Mdivi-1

Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.

Figure 3A–B and Figure 4E; Results, Effect of Fission Inhibitors on Oxidative Stress and cell viability paragraph; Cell Culture and Inhibitor Applications

Fraction of ROS-positive cells: Muse Oxidative Stress Kit cytometry; Figure 3B mean ± SEM of three independent experiments. Representative flow percentages are not group means and are not extracted. — Figure 3A–B, official legend and oxidative-stress Results

MTT absorbance after inhibitor exposure: Figure 4E, mean ± SEM of three independent experiments; MTT assay measured absorbance at 570 nm. — Figure 4E and official legend; viability Results and MTT methods

Mdivi-1 In Vivo Studies

In young and old mice pretreated with 50 mg/kg mdivi-1, ischemia–reperfusion limbs still showed lower complex I-linked muscle respiration than contralateral limbs. Because all mice received mdivi-1, the study documents persistent impairment during treatment but does not provide a concurrent vehicle-controlled estimate of protection. [3]

Persistent limb respiratory impairment in mdivi-1-treated mice

Animal study · Male C57Bl6J mice, 23 weeks (n = 7) and 83 weeks (n = 6 analyzed from 7 initially) [3]

Complex I-linked respiration was lower in the ischemia–reperfusion limb than the contralateral limb despite pretreatment. All mice received mdivi-1; this within-animal comparison does not quantify efficacy versus an untreated or vehicle-treated mouse group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Complex I-linked OXPHOS: IR limb versus contralateral limbMean ± SEM 10.28 ± 4.16 vs. 34.98 ± 2.25 pmol/(s×mg wet weight), P < 0.0001[3]
Complex I-linked OXPHOS: IR limb versus contralateral limbMean ± SEM 3.97 ± 0.79 vs. 32.11 ± 2.37 pmol/(s×mg wet weight), P < 0.0001[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Once
Treatment course
1 h before 2 h ischemia followed by 2 h reperfusion
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
23-week mice receiving mdivi-1
50 mg/kg
Non-ischemic contralateral limb of the same treated animal; no parallel vehicle groupLower complex I-linked OXPHOS in the IR limb than the contralateral limb; no controlled drug-effect estimate.[3]
83-week mice receiving mdivi-1
50 mg/kg
Non-ischemic contralateral limb of the same treated animal; no parallel vehicle groupLower complex I-linked OXPHOS in the IR limb than the contralateral limb; no controlled drug-effect estimate.[3]
23-week mice receiving mdivi-1
Model: 23-week, n = 7
Reported limits: Vehicle not specified in acquired methods; systemic mdivi-1 exposure also applies to the contralateral control.
83-week mice receiving mdivi-1
Model: 83-week, n = 6 analyzed; one of seven died during reperfusion
Reported limits: Vehicle not specified in acquired methods; systemic mdivi-1 exposure also applies to the contralateral control.
Methods and source locations

Compound reported in the paper: Mdivi-1

Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.

Figure 2A and Figure 6; Results 2.2.1; Materials and Methods 4.1–4.4 and 4.8; Discussion 3.3 and 3.5

Complex I-linked OXPHOS: IR limb versus contralateral limb: Permeabilized gastrocnemius fibers; ADP-stimulated oxymetry. 23-week mice, n = 7 analyzed. — Figure 2A; Results 2.2.1; Methods 4.2, 4.4 and 4.8

Complex I-linked OXPHOS: IR limb versus contralateral limb: Permeabilized gastrocnemius fibers; ADP-stimulated oxymetry. 83-week mice, n = 6 analyzed. — Figure 2A; Results 2.2.1; Methods 4.2, 4.4 and 4.8

23-week mice receiving mdivi-1 · Figure 2A and Figure 6; Methods 4.1–4.4

83-week mice receiving mdivi-1 · Figure 2A and Figure 6; Methods 4.1–4.4

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 338967-87-6
Applications

DRP1 inhibitor

Formula C15H10Cl2N2O2S
Molecular Weight 353.22
SMILES
COC1=C(C=C(C(=C1)N2C(=O)C3=CC=CC=C3NC2=S)Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 62 mg/mL (175.52 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
6 mg/mL
Vehicle
5% DMSO+40% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Mdivi-1 Research References

  1. [1] Bordt EA, Clerc P, Roelofs BA, et al. The Putative Drp1 Inhibitor mdivi-1 Is a Reversible Mitochondrial Complex I Inhibitor that Modulates Reactive Oxygen Species Developmental cell (2017). PMID: 28350990 DOI: 10.1016/j.devcel.2017.02.020 Source material
  2. [2] Umut Kerem Kolaç, Gizem Donmez Yalcin, Abdullah Yalcin. Chemical Inhibition of Mitochondrial Fission Improves Mitochondrial Function and Subdues Hyperglycemia Induced Stress in Placental Trophoblast Cells Research Square (preprint, version 1) (2022). DOI: 10.21203/rs.3.rs-1706968/v1 Source material
  3. [3] Paradis S, Charles AL, Giannini M, et al. Targeting Mitochondrial Dynamics during Lower-Limb Ischemia Reperfusion in Young and Old Mice: Effect of Mitochondrial Fission Inhibitor-1 (mDivi-1) International journal of molecular sciences (2024). PMID: 38612835 DOI: 10.3390/ijms25074025 Source material

Publications

2 publications citing this product

  1. Umut Kerem Kolac, .et al. , Mol Biol Rep, 2023, Jan;50(1):493-506 PMID: 36352179
  2. KOLAC UK, .et al. , Research Square, 2022, 03 Jun

Added to your cart

View Cart Checkout
Loading...